MedTrace Logo

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

NCT03490786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-04-06

No results posted yet for this study

Summary

Dose escalation study of GT-001

Conditions

  • Feeding and Eating Disorders

Interventions

DRUG

GT-001

PK, PD Study to Determine Safety of Escalating Doses of GT-001

Sponsors & Collaborators

  • Gila Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-16
Primary Completion
2017-08-09
Completion
2017-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490786 on ClinicalTrials.gov